Navigation Links
Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members
Date:7/13/2009

RICHMOND, Va., July 13 /PRNewswire-FirstCall/ -- Long term care costs in Idaho continue to rise at a rate outpacing inflation, putting significant financial pressure on those in or near retirement. As a leader in the long term care insurance industry, Genworth offers a suite of insurance products to help people proactively plan for their future. Now, AARP(R) members that reside in Idaho can take advantage of a new program designed to simplify the process of purchasing affordable long term care insurance.

Genworth Financial, Inc. (NYSE: GNW) today introduced My Future, My Plan(SM), a suite of long term care insurance plans created exclusively for AARP members. My Future, My Plan is the result of Genworth combining its unique expertise in the area of the long term care insurance product with what it has learned about AARP's demographic. With My Future, My Plan, AARP members get access to industry-leading features while maintaining the ability to customize a plan that falls within their price range, meeting their lifestyle needs. In three simple steps, AARP members can choose one of three preselected long term care insurance plans, tailored to them and designed specifically to reflect membership demographics. All plans include the option of home care, assisted living and nursing home services along with flexible features designed exclusively for AARP members. Also included is no-cost access to Genworth's Privileged Care(R) Coordinators who assist policyholders and their families in planning for their long term care.

AARP members have three easy options available to find out more about My Future, My Plan: by scheduling a free, no obligation "readiness review" with an "Authorized to Offer" Genworth insurance agent in person or by calling 800 565.0805, or by visiting genworth.com/aarp'/>"/>

SOURCE Genworth Financial, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Growth in Wyoming Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
2. Growth in Wisconsin Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
3. Growth in Washington Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
4. Growth in Virginia Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
5. Growth in Utah Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
6. Growth in Texas Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
7. Growth in Rhode Island Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
8. Video: Genworth Financial Reveals Best Places in America for Long Term Care
9. Growth in Ohio Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
10. Growth in North Dakota Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
11. Growth in North Carolina Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 1Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 2Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin An Investigational Treatment for Type 2 Diabetes 4914 3IBM Scientists First to Image the Anatomy of a Molecule 4913 1IBM Scientists First to Image the Anatomy of a Molecule 4913 2IBM Scientists First to Image the Anatomy of a Molecule 4913 3IBM Scientists First to Image the Anatomy of a Molecule 4913 4IBM Scientists First to Image the Anatomy of a Molecule 4913 5Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 1Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 2Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 3Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 4Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 5Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 6Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 7Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 8Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 9